Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Placebo-controlled Study
100%
Intermittent Claudication
100%
Proteinuria
100%
Basic Fibroblast Growth Factor (bFGF)
100%
Efficacy Endpoint
37%
Clinical Trials
25%
Claudication
25%
Limb Blood Flow
25%
Randomized Double-blind
12%
Placebo-controlled
12%
Phase II Trial
12%
Intravenous Infusion
12%
Peripheral Arterial Disease
12%
Angiogenesis
12%
Quality of Life
12%
Renal Function
12%
Intravenous Administration
12%
Dosing Schedule
12%
Validated Questionnaire
12%
No Significant Difference
12%
Total Dose
12%
Route of Administration
12%
Graded Exercise
12%
Small Sample Size
12%
Walking Time
12%
Functional Capacity
12%
Functional Status
12%
Common Symptoms
12%
Functional Quality
12%
Relative Efficacy
12%
Relative Safety
12%
Angiogenic Molecules
12%
Alternative Dosing Schedule
12%
Drug Administration Routes
12%
Severe Impairment
12%
Hindlimb Ischemia
12%
Treadmill Protocol
12%
Control Phase
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo-Controlled Study
100%
Fibroblast Growth Factor 2
100%
Proteinuria
100%
Intermittent Claudication
100%
Clinical Trial
25%
Claudication
25%
Functional Status
25%
Phase II Trials
12%
Drug Administration
12%
Route of Administration
12%
Placebo
12%
Ischemia
12%
Peripheral Occlusive Artery Disease
12%
Low Drug Dose
12%